• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Oncology

Sacituzumab govitecan increased survival in metastatic triple-negative breast cancer

bySze Wah Samuel ChanandHarsh Shah
April 27, 2021
in Oncology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Sacituzumab govitecan was shown to significantly increase overall survival in previously treated metastatic triple-negative breast cancer patients compared to single-agent chemotherapy treatment.

2. Sacituzumab govitecan was associated with more frequent events of myelosuppression and diarrhea compared to chemotherapy treatment.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Breast cancer patients with triple-negative status have significantly worse outcomes in the metastatic settings compared to their receptor-positive counterparts. In triple-negative patients that progress on chemotherapy, single-agents are the next step; however, the response is poor. Sacituzumab govitecan is an antibody-drug conjugate that targets antitrophoblast cell-surface antigen 2, a receptor that is highly expressed in breast cancer, coupled with SN-38, a metabolite of the chemotherapy, irinotecan, a topoisomerase I inhibitor. In this trial of metastatic triple-negative breast cancer patients who had progressed on two or more previous standard chemotherapy regimens, patients were randomized to sacituzumab govitecan or a pre-determined standard of care single-agent chemotherapy. Sacituzumab govitecan demonstrated superior progress-free survival and overall survival compared to single-agent chemotherapy. Adverse events were higher in the sacituzumab govitecan group and included neutropenia, diarrhea, anemia, and febrile neutropenia. The study limitation was the heterogeneity of the chemotherapy drugs, which may have contributed to variable toxicity profiles in the comparator group. In general, this clinical trial demonstrated sacituzumab govitecan was superior for prolonging overall survival compared to single-agent chemotherapy.

Click here to read the study in the NEJM

Relevant Reading: Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)

RELATED REPORTS

#VisualAbstract: Adjuvant Atezolizumab Does Not Provide Benefit in Early Triple-Negative Breast Cancer

#VisualAbstract: Camrelizumab with Chemotherapy is an Effective Neoadjuvant Therapy in Patients With Triple-Negative Breast Cancer

Addition of pembrolizumab to chemotherapy improves early-stage triple-negative breast cancer survival

In-Depth [randomized controlled trial]: This was a multicenter, randomized, open-label trial of 468 patients at 88 sites in seven countries. Patients with metastatic triple-negative breast cancer who progressed on two or more standard chemotherapy lines of therapy including a taxane in any indication were included in the study. Patients with brain metastases were excluded from the primary analysis. Patients were randomized in a 1:1 ratio to receive the sacituzumab govitecan or single-agent chemotherapy such as eribulin, vinorelbine, capecitabine, or gemcitabine, respectively. The primary endpoint was progression-free survival. Sacituzumab govitecan (5.6 months) had a significantly higher progression-free survival compared to the control group (1.7 months) (hazard ratio for progression or death [HR]; 0.41, 95% confidence interval [CI], 0.32 to 0.52; P < 0.001). Furthermore, sacituzumab govitecan (12.1 months) showed significantly longer overall survival compared to the control group (6.7 months) (HR, 0.48; 95% CI, 0.38 to 0.59; P < 0.001). Grade 3 or higher adverse events were higher in sacituzumab govitecan group, which included more neutropenia (sacituzumab govitecan, 51%; chemotherapy, 33%), diarrhea (sacituzumab govitecan, 10%; chemotherapy, <1%), and anemia (sacituzumab govitecan, 8%; chemotherapy, 5%). Treatment discontinuations were similar between both groups. Overall, this large clinical trial demonstrated the efficacy of using an antibody-drug conjugate in cancer treatment to prolong overall survival in metastatic triple-negative breast cancer.

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: metastatic breast cancerSacituzumab govitecantriple negative breast cancer
Previous Post

Long term outcomes following surgical interventions for endometriosis

Next Post

Microbiota-directed food intervention showed benefits for undernourished children

RelatedReports

#VisualAbstract: Adjuvant Atezolizumab Does Not Provide Benefit in Early Triple-Negative Breast Cancer
StudyGraphics

#VisualAbstract: Adjuvant Atezolizumab Does Not Provide Benefit in Early Triple-Negative Breast Cancer

February 12, 2025
#VisualAbstract: Camrelizumab with Chemotherapy is an Effective Neoadjuvant Therapy in Patients With Triple-Negative Breast Cancer
StudyGraphics

#VisualAbstract: Camrelizumab with Chemotherapy is an Effective Neoadjuvant Therapy in Patients With Triple-Negative Breast Cancer

January 9, 2025
Preoperative bilateral breast imaging may reduce contralateral cancer recurrence
Oncology

Addition of pembrolizumab to chemotherapy improves early-stage triple-negative breast cancer survival

December 16, 2024
One-year of Herceptin preferable to two-year regimen
Chronic Disease

Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer

September 30, 2024
Next Post
Improved glycemic control in type 1 diabetics on very low-carbohydrate diets

Microbiota-directed food intervention showed benefits for undernourished children

Surgical site anesthetic infusion may enhance analgesia after mastectomy

Replacement of infusion sets every seven days may be safe and cost-effective to prevent life-threatening catheter-related bloodstream infections

#VisualAbstract: Aspirin treatment without indication in patients on direct oral anticoagulants may increase the risk of bleeding events

#VisualAbstract: Aspirin treatment without indication in patients on direct oral anticoagulants may increase the risk of bleeding events

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Tirzepatide-associated improvements in cardiometabolic risk factors linked to degree of weight loss
  • Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
  • 2 Minute Medicine Rewind June 23, 2025
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.